WO1994026787A1 - Method for generating cell type specific phage antibody libraries - Google Patents

Method for generating cell type specific phage antibody libraries Download PDF

Info

Publication number
WO1994026787A1
WO1994026787A1 PCT/US1994/005124 US9405124W WO9426787A1 WO 1994026787 A1 WO1994026787 A1 WO 1994026787A1 US 9405124 W US9405124 W US 9405124W WO 9426787 A1 WO9426787 A1 WO 9426787A1
Authority
WO
WIPO (PCT)
Prior art keywords
target cells
cell
phage particles
phage
target
Prior art date
Application number
PCT/US1994/005124
Other languages
French (fr)
Inventor
William T. Tse
Irving L. Weissman
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of WO1994026787A1 publication Critical patent/WO1994026787A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/02Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1037Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display

Definitions

  • the invention relates generally to the field of cell type specific phage antibody libraries, and relates specifically to the field of generating such libraries by direct affinity selection on the surface of target cells.
  • the phage antibody technology is a recently developed technique that allows the expression of monoclonal antibodies on the surface of filamentous phage particles (see, for example, Smith, Science 228, 1315-1317 (1985); Barbas et al., Proc. Natl. Acad. Sci. USA 88, 7978-7982 (1991); Clackson et al., Nature 352, 624-628 (1991)).
  • One advantage of this technology is the linkage of the specificity of a monoclonal antibody with the genetic information encoding the specificity in the same phage particle, thus allowing enrichment of specific phage antibodies by binding to purified antigens attached to a solid phase, followed by elution and amplification of the phage particles.
  • Such a method is described in Kang et al., Proc.Natl.Acad.Sci.USA 88, 4363-4366 (1991).
  • micropanning or affinity column techniques researchers have used this technology to generate antibodies reactive to well-characterized antigens that can be purified in large quantities, either as natural or recombinant products, including various hapterts, tetanus toxoid, HTV and RSV glycoproteins, HBV core and surface antigens, progesterone, thyroglobulin, TNF alpha, CEA, soluble CD4, IL2R p55 chain, lysozyme, bovine serum albumin, trypsin, anhydrotrypsin, and L6 tumor-associated antigen.
  • natural or recombinant products including various hapterts, tetanus toxoid, HTV and RSV glycoproteins, HBV core and surface antigens, progesterone, thyroglobulin, TNF alpha, CEA, soluble CD4, IL2R p55 chain, lysozyme, bovine serum albumin, trypsin, anhydro
  • the present invention involves methods for using the phage antibody technology to generate antibodies directed against previously unknown and unpurified antigens on the cell surface, e.g., as a way to discover new antigens on important cell types. Since a phage antibody may be amplified by growing the phage in bacteria, it is possible to recover a single phage particle specifically bound to an antigen in order to generate enough monoclonal antibodies for detailed characterization of the antigen. The high sensitivity of the method enables isolation of antibodies directed against an unpurified antigen in the midst of numerous background antigens.
  • target antigens on the surface of a phenotypically defined population of cells are used to separate phage antibodies reactive to the antigens from the background.
  • the cell membrane of the target cells can be considered a solid phase support for a set of cell type specific antigens, and the intact target cells can be used as a convenient physical device to separate phage antibodies bound on the surface of the target cells from the unbound phage antibodies.
  • the inventive method for generating antibodies against previously uncharacterized and unpurified antigens on the surface of target cells in a cell population includes incubating a combinatorial library of antibodies expressed on the surface of filamentous phage particles with a target cell population under conditions sufficient to bind a portion of the phage particles to the target cells.
  • the target cells and bound phage particles are then separated from the unbound phage particles, and the bound phage particles are recovered.
  • These phage particles are then amplified to create an enriched library.
  • Monoclonal antibodies specific to the target cell are then isolated from the enriched library for subsequent use.
  • the phage antibody library may be preadsorbed with an excess of non-target cells to immunologically remove antibodies directed against antigens present on non-target cells.
  • the adsorption step may be performed after the phage antibody selection and amplification, or prior to the initial incubating step.
  • the removal of these antibodies can be done by subtraction hybridization of DNA from a phage antibody library enriched with the target cells to DNA from a library enriched with non-target cells.
  • the phenotypically defined target cell population may be isolated prior to incubating the target cells with the phage antibody library, or the target cells may be a subpopulation within a heterogeneous cell population and be isolated after incubating with the phage antibody library, thus copurifying the phage antibodies bound to the cell surface antigens.
  • FIGURE 1 is a flow chart illustrating an embodiment of the present inventive method.
  • FIGURE 2 is a flow chart illustrating another embodiment of the present inventive method.
  • FIGURES 3a - 3d are histograms showing indirect immunofluorescence patterns of KGla cells and mouse thymocytes stained with the unenriched and enriched antibody libraries.
  • the abscissa indicates relative fluorescence intensity, and the ordinate indicates relative cell number.
  • the process of the present invention includes a method to generate antibodies against cell surface antigens by direct affinity selection of phage antibodies on the surface of target cells.
  • a phage antibody library is constructed by standard methods and an aliquot of the library is used for incubation with the target cells.
  • Phage antibodies that are specific to and have a high affinity for antigens on the target cells will tightly bind to the cells and can be separated from the rest of the phage antibody library by washing and spinning down the cells.
  • the bound phage particles can then be eluted from the cell surface, recovered, and amplified to yield an enriched phage antibody library.
  • the present method involves a first step of incubating (100) a standard phage antibody library, such as a combinatorial library of antibodies expressed on the surface of filamentous phage particles, with a target cell population.
  • a standard phage antibody library such as a combinatorial library of antibodies expressed on the surface of filamentous phage particles
  • the cells are incubated under conditions sufficient to bind a portion of the phage particles to the target cells.
  • the target cell population is an isolated cell population.
  • the process of the present invention preferably utilizes a standard combinatorial phage antibody library of 10 ⁇ recombinants, which may be prepared using standard protocols, such as that described in Barbas et al., Methods 2, 119-124 (1991).
  • the cell population may be isolated according to any preselected criteria.
  • the target cells and the phage particles bound thereto are separated (102) from the unbound phage particles.
  • Phage antibodies that are specific to and have a high affinity for antigens on the target cells will tightly bind to the cells and can be separated from the rest of the phage antibody library by centrifugating the cells through a calf serum cushion.
  • Other standard separation methods known by those skilled in the relevant art may be used, examples including but not limited to, cell washing and centrifugation, filtration of the unbound phages through a membrane, and immobilization or capture of the cells on a solid phase.
  • the separated phage particles, or phage antibodies, are then recovered (104).
  • the bound phage particles may be eluted, for example using an acidic buffer, from the cell surface using standard methods.
  • the resulting recovered phage antibodies are amplified (106) to yield an enriched phage antibody library. Repeating this enrichment step several times generates a phage antibody library with high specificity for surface antigens on the target cells. Each round of enrichment increases the representation of antibodies with higher affinity for the target antigens but decreases the diversity of the library. Thus, the amount of enrichment will depend on the particular requirements of the user.
  • monoclonal antibodies specific for the target cells are isolated (108) from the library.
  • phage antibodies reactive to antigens on the target cell population are obtained.
  • the monoclonal antibodies are isolated (108) using methods known and available to those skilled in the art.
  • direct affinity selection of the phage antibodies on the cell surface is used as described substantially above.
  • a population of isolated target cells are incubated with the phage antibody library.
  • the target cells may be in the form of a cell line, or other substantially isolated population of target cells.
  • the target cell population is a subpopulation from a heterogeneous cell population before any isolation.
  • the target cell population may subsequently be separated (110) from other cells in the heterogeneous population based on phenotypic distinctions, or other appropriate distinctions, thus copurifying the phage particles bound to the cell surface (112).
  • the target cells are phenotypically defined target cell subpopulations.
  • This allows generation of antibodies against rare but phenotypically defined cell subpopulations that are too few in cell number to allow characterization by conventional methods.
  • the phage antibody library is first allowed to bind to the total and unpurified cell population.
  • the target subpopulation is then physically separated from the rest of the cells by means of its defining phenotypic characteristics.
  • the phage particles specifically bound to the surface antigens of the target cells are separated (112) out together with the target cell subpopulation.
  • phage antibodies reactive to antigens on the target subpopulation of a heterogeneous population may be selectively enriched by copurification of the target cells with their specific phage antibodies, exploiting the phenotypic characteristics of the target cells. Standard methods of cell separation known to those skilled in the art may be used.
  • the method to be used for the copurification (112) step may be any of the type known and available to those skilled in the art.
  • Exemplary methods applicable to target cells in suspension include fluorescence-activated cell sorting (FACS), immunological panning, magnetic bead separation, and affinity chromatography.
  • FACS fluorescence-activated cell sorting
  • the specific copurification method will depend on availability of materials, the type of target cell subpopulation, and other factors determinable by those skilled in the art.
  • the cell population used in conjunction with the present method may include whole tissue sections, such as frozen tissue sections, in which the target cell population is identifiable. Exemplary methods for identifying and isolating target cell subpopulations may include use of immunohistochemical markers, physical location of cell populations, or other methods known and used by those skilled in the art.
  • tissue sections the tissue section is incubated with the phage antibody library under conditions sufficient to bind phage particles to the target cells. The target cells and the bound phage particles are then microdissected from the tissue section, the phage particles are recovered and amplified, and monoclonal antibodies are isolated in accordance with the method described above.
  • the preferred embodiment of the invention makes use of the phenotypic characteristics of the target cells to identify phage antibodies of interest by means of their binding to the target cells.
  • phage antibodies are selected if they are shown to have an identifiable and preselected function, as compared with other phage antibodies without such function.
  • phage antibodies may be assayed, for example, for the functional consequences of a phage antibody-target cell binding.
  • One assay may be to measure intracellular calcium concentration.
  • Another effective assay may be used to detect cell activation, cell proliferation, or cell killing, or the blocking of these activities.
  • Yet another assay may be to analyze the expression of preselected genes.
  • Other functional methods of identifying phage antibodies known and available to those skilled in the art may be used.
  • the resulting phage antibody library may contain antibodies reactive to antigens unique to the target cells and antibodies reactive to antigens present on both the target cells and non-target cells. It may be desirable to selectively remove the antibodies reactive to antigens not unique to the target cells. This may be accomplished by preadsorbing the phage antibody library with an excess of non-target cells to immunologically remove phage antibodies directed against antigens present on non-target cells. This additional step may be performed either prior to incubating the phage antibody library with the cell population, or prior to isolating monoclonal antibodies from the enriched library.
  • the goal of selectively enriching phage antibodies directed against antigens present only on target cells and not on non-target cells can also be achieved by DNA subtraction hybridization.
  • two cell type specific phage antibody libraries are generated using the present inventive method, one for the target cells and one for the non-target cells.
  • DNA encoding antibodies directed against antigens present on both cell types are then removed from the first library by hybridizing DNA from the first library to an excess of DNA from the second library and subsequently removing the annealed hybrids.
  • the resulting subtracted phage antibody library will then contain mostly antibodies directed against antigens unique to the target cells. Standard methods of DNA subtraction hybridization known to those skilled in the relevant art, or variations of these methods, may be used in this step.
  • KGla cell line is an available human myeloblastoid cell line, and is characterized in several publications, including Koeffler et al., Blood 56, 265-273 (1980).
  • spleen cells are isolated from the animals, lymphocytes are separated on a Ficoll-PaqueTM gradient, commercially available from Pharmacia LKB Biotechnology, Inc., Piscataway, New Jersey, and total RNA is prepared using standard, known techniques.
  • a combinatorial phage antibody library of 10 ⁇ recombinants is prepared using standard protocols as described in Barbas et al., Methods 2, 119-124 (1991), and as described in further detail below.
  • KGla cells are incubated with phage particles from the combinatorial library in binding buffer on ice for 30 minutes, and then spun through a calf serum cushion three times. Phage particles bound to the surface of the cells are eluted in an acid buffer (such as 0.1 M HC1, adjusted with glycine to pH 2.2; and BSA lmg/ml), recovered, and used to infect XLl-Blue bacteria, available from Stratagene Cloning Systems, La Jolla, California. The phagemids in the infected bacteria are expanded in culture and rescued with helper phage VCSM13 to yield an enriched phage antibody library. The library is then used in another round of enrichment.
  • an acid buffer such as 0.1 M HC1, adjusted with glycine to pH 2.2; and BSA lmg/ml
  • Table 1 lists the number of phage particles recovered after each round of enrichment, showing a steady increase in the number of recovered phage particles after each round.
  • a negative control experiment (results not shown) using mouse thymocytes as the target cells for binding with the phage shows no increase in the number of phage particles recovered.
  • FIGURES 3(a) through 3(d) are histograms showing fluorescence patterns of KGla cells and mouse thymocytes stained with the unenriched (a,c) or enriched (b,d) antibody libraries. The abscissa indicates relative fluorescence intensity and the ordinate indicates relative cell number.
  • Fab fragments are produced separately from ten individual clones picked at random from the library. FACS analysis of these samples (results not given) shows that the Fab fragments from all of the ten clones strongly react with KGla cells and with variable patterns, indicating that all of the ten monoclonal antibodies are specific for KGla and probably recognize at least several different surface antigens on the cells.
  • the entire enriched antibody library most likely contains a large number of monoclonal antibodies recognizing many different surface antigens on KGla cells.
  • KGla cells which bear the human CD34 antigen on their surface, are stained with CD34-specific antibodies according to Civin et al., T.Immunol 133, 157-165 (1984), and spiked at a ratio of 1 to 10 or 1 to 100 into mouse thymocytes, which are CD34 antigen negative.
  • the cell mixtures are incubated with an unenriched phage antibody library and sorted for CD34 antigen positive (CD34+) cells by FACS. Phage particles bound on the surface of the sorted cells are recovered by acid elution and used to infect XLl-Blue bacteria.
  • An enriched phage antibody library is then produce by helper phage rescue of the phagemids in the infected bacteria and used in another round of enrichment.
  • Table 2 the number of phage particles recovered from the sorted CD34+ cells increases dramatically after three rounds of selection, suggesting effective enrichment of specific phage antibody by the copurification method described in detail above.
  • Fab fragments are produced from the enriched library and used for staining KGla and mouse thymocytes. FACS analysis using these Fab fragments show a strong reaction with the KGla cells but no reaction with the mouse thymocytes (results not shown). Fab fragments from the unenriched library give signals similar to the background. This result demonstrates the feasibility of producing specific monoclonal antibodies directed against a rare population of cells using the combined strategies of cell surface selection and target cell copurification.

Abstract

A method for generating monoclonal antibodies directed against previously uncharacterized an unpurified antigens on the surface of target cells in a cell population. The method includes incubating (100) a combinatorial library of antibodies expressed on the surface of filamentous phage particles with a target cell population under conditions sufficient to bind a portion of the phage particles to the target cells. The target cells and bound phage particles are then separated (102) from the unbound phage particles, and the bound phage particles are recovered (104). These phage particles are then amplified (106) to create an enriched library. Monoclonal antibodies specific to the target cell are then isolated (108) from the enriched library for subsequent use.

Description

Method for Generating Cell Type Specific Phage Antibody Libraries
BACKGROUND OF THE INVENTION
The invention was supported by a grant of the National Institute of Health/National Cancer Institute, Grant No. CA-42551, under which the government may have rights.
Field of the Invention
The invention relates generally to the field of cell type specific phage antibody libraries, and relates specifically to the field of generating such libraries by direct affinity selection on the surface of target cells.
Although the generation of antibody libraries, and more specifically phage antibody libraries, has been done for selected, purified antigens, a method for generating cell type specific phage antibody libraries for identifying, characterizing, and cloning new surface molecules on intact, whole cells has not been developed. Such cell surface molecules are likely to be mediators of important biological functions and may be used in clinical applications as targets for pharmacological intervention and surface markers for identification, purification, and phenotypic dissection of the target cells.
Brief Description of Background Art
The phage antibody technology is a recently developed technique that allows the expression of monoclonal antibodies on the surface of filamentous phage particles (see, for example, Smith, Science 228, 1315-1317 (1985); Barbas et al., Proc. Natl. Acad. Sci. USA 88, 7978-7982 (1991); Clackson et al., Nature 352, 624-628 (1991)).
One advantage of this technology is the linkage of the specificity of a monoclonal antibody with the genetic information encoding the specificity in the same phage particle, thus allowing enrichment of specific phage antibodies by binding to purified antigens attached to a solid phase, followed by elution and amplification of the phage particles. Such a method is described in Kang et al., Proc.Natl.Acad.Sci.USA 88, 4363-4366 (1991). Using micropanning or affinity column techniques, researchers have used this technology to generate antibodies reactive to well-characterized antigens that can be purified in large quantities, either as natural or recombinant products, including various hapterts, tetanus toxoid, HTV and RSV glycoproteins, HBV core and surface antigens, progesterone, thyroglobulin, TNF alpha, CEA, soluble CD4, IL2R p55 chain, lysozyme, bovine serum albumin, trypsin, anhydrotrypsin, and L6 tumor-associated antigen.
However, none of these methods involve using the phage antibody technology to generate antibodies directed against previously unknown and unpurified antigens, including cell surface antigens. Accordingly, there remains a need for a method for rapidly generating monoclonal antibodies directed against unpurified surface antigens on phenotypically defined cell populations using this technology.
SUMMARY OF THE INVENTION
The present invention involves methods for using the phage antibody technology to generate antibodies directed against previously unknown and unpurified antigens on the cell surface, e.g., as a way to discover new antigens on important cell types. Since a phage antibody may be amplified by growing the phage in bacteria, it is possible to recover a single phage particle specifically bound to an antigen in order to generate enough monoclonal antibodies for detailed characterization of the antigen. The high sensitivity of the method enables isolation of antibodies directed against an unpurified antigen in the midst of numerous background antigens.
In the present invention, target antigens on the surface of a phenotypically defined population of cells are used to separate phage antibodies reactive to the antigens from the background. The cell membrane of the target cells can be considered a solid phase support for a set of cell type specific antigens, and the intact target cells can be used as a convenient physical device to separate phage antibodies bound on the surface of the target cells from the unbound phage antibodies.
The inventive method for generating antibodies against previously uncharacterized and unpurified antigens on the surface of target cells in a cell population includes incubating a combinatorial library of antibodies expressed on the surface of filamentous phage particles with a target cell population under conditions sufficient to bind a portion of the phage particles to the target cells. The target cells and bound phage particles are then separated from the unbound phage particles, and the bound phage particles are recovered. These phage particles are then amplified to create an enriched library. Monoclonal antibodies specific to the target cell are then isolated from the enriched library for subsequent use. To selectively enrich phage antibodies direct against antigens unique to the target cells, the phage antibody library may be preadsorbed with an excess of non-target cells to immunologically remove antibodies directed against antigens present on non-target cells. The adsorption step may be performed after the phage antibody selection and amplification, or prior to the initial incubating step. Alternatively, the removal of these antibodies can be done by subtraction hybridization of DNA from a phage antibody library enriched with the target cells to DNA from a library enriched with non-target cells. The phenotypically defined target cell population may be isolated prior to incubating the target cells with the phage antibody library, or the target cells may be a subpopulation within a heterogeneous cell population and be isolated after incubating with the phage antibody library, thus copurifying the phage antibodies bound to the cell surface antigens.
BRIEF DESCRIPTION OF THE FIGURES
FIGURE 1 is a flow chart illustrating an embodiment of the present inventive method.
FIGURE 2 is a flow chart illustrating another embodiment of the present inventive method.
FIGURES 3a - 3d are histograms showing indirect immunofluorescence patterns of KGla cells and mouse thymocytes stained with the unenriched and enriched antibody libraries. The abscissa indicates relative fluorescence intensity, and the ordinate indicates relative cell number.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
The process of the present invention includes a method to generate antibodies against cell surface antigens by direct affinity selection of phage antibodies on the surface of target cells. Generally, a phage antibody library is constructed by standard methods and an aliquot of the library is used for incubation with the target cells. Phage antibodies that are specific to and have a high affinity for antigens on the target cells will tightly bind to the cells and can be separated from the rest of the phage antibody library by washing and spinning down the cells. The bound phage particles can then be eluted from the cell surface, recovered, and amplified to yield an enriched phage antibody library.
As illustrated in the flow chart of FIGURE 1, the present method involves a first step of incubating (100) a standard phage antibody library, such as a combinatorial library of antibodies expressed on the surface of filamentous phage particles, with a target cell population. The cells are incubated under conditions sufficient to bind a portion of the phage particles to the target cells. In the embodiment of FIGURE 1, the target cell population is an isolated cell population. The process of the present invention preferably utilizes a standard combinatorial phage antibody library of 10^ recombinants, which may be prepared using standard protocols, such as that described in Barbas et al., Methods 2, 119-124 (1991). The cell population may be isolated according to any preselected criteria.
Following incubation (100), the target cells and the phage particles bound thereto are separated (102) from the unbound phage particles. Phage antibodies that are specific to and have a high affinity for antigens on the target cells will tightly bind to the cells and can be separated from the rest of the phage antibody library by centrifugating the cells through a calf serum cushion. Other standard separation methods known by those skilled in the relevant art may be used, examples including but not limited to, cell washing and centrifugation, filtration of the unbound phages through a membrane, and immobilization or capture of the cells on a solid phase. The separated phage particles, or phage antibodies, are then recovered (104). The bound phage particles may be eluted, for example using an acidic buffer, from the cell surface using standard methods. The resulting recovered phage antibodies are amplified (106) to yield an enriched phage antibody library. Repeating this enrichment step several times generates a phage antibody library with high specificity for surface antigens on the target cells. Each round of enrichment increases the representation of antibodies with higher affinity for the target antigens but decreases the diversity of the library. Thus, the amount of enrichment will depend on the particular requirements of the user.
Once the enriched library is generated, monoclonal antibodies specific for the target cells are isolated (108) from the library. Thus, phage antibodies reactive to antigens on the target cell population are obtained. The monoclonal antibodies are isolated (108) using methods known and available to those skilled in the art.
In one form of the invention, direct affinity selection of the phage antibodies on the cell surface is used as described substantially above. In that instance, a population of isolated target cells are incubated with the phage antibody library. The target cells may be in the form of a cell line, or other substantially isolated population of target cells.
In an alternative embodiment, and as illustrated in FIGURE 2, the target cell population is a subpopulation from a heterogeneous cell population before any isolation. After incubation with the phage antibody library, the target cell population may subsequently be separated (110) from other cells in the heterogeneous population based on phenotypic distinctions, or other appropriate distinctions, thus copurifying the phage particles bound to the cell surface (112).
Preferably, using the copurification (110) method illustrated in FIGURE 2, the target cells are phenotypically defined target cell subpopulations. This allows generation of antibodies against rare but phenotypically defined cell subpopulations that are too few in cell number to allow characterization by conventional methods. In this embodiment of the inventive method, the phage antibody library is first allowed to bind to the total and unpurified cell population. The target subpopulation is then physically separated from the rest of the cells by means of its defining phenotypic characteristics. The phage particles specifically bound to the surface antigens of the target cells are separated (112) out together with the target cell subpopulation.
The separated phage particles can then be recovered (114), amplified (116), and used in another round of enrichment in a manner similar to that described above. Thus, phage antibodies reactive to antigens on the target subpopulation of a heterogeneous population may be selectively enriched by copurification of the target cells with their specific phage antibodies, exploiting the phenotypic characteristics of the target cells. Standard methods of cell separation known to those skilled in the art may be used.
The method to be used for the copurification (112) step may be any of the type known and available to those skilled in the art. Exemplary methods applicable to target cells in suspension include fluorescence-activated cell sorting (FACS), immunological panning, magnetic bead separation, and affinity chromatography. The specific copurification method will depend on availability of materials, the type of target cell subpopulation, and other factors determinable by those skilled in the art.
The cell population used in conjunction with the present method may include whole tissue sections, such as frozen tissue sections, in which the target cell population is identifiable. Exemplary methods for identifying and isolating target cell subpopulations may include use of immunohistochemical markers, physical location of cell populations, or other methods known and used by those skilled in the art. In practicing the present invention using tissue sections, the tissue section is incubated with the phage antibody library under conditions sufficient to bind phage particles to the target cells. The target cells and the bound phage particles are then microdissected from the tissue section, the phage particles are recovered and amplified, and monoclonal antibodies are isolated in accordance with the method described above.
The preferred embodiment of the invention makes use of the phenotypic characteristics of the target cells to identify phage antibodies of interest by means of their binding to the target cells. In an alternative embodiment, phage antibodies are selected if they are shown to have an identifiable and preselected function, as compared with other phage antibodies without such function.
In that embodiment, phage antibodies may be assayed, for example, for the functional consequences of a phage antibody-target cell binding. One assay may be to measure intracellular calcium concentration. Another effective assay may be used to detect cell activation, cell proliferation, or cell killing, or the blocking of these activities. Yet another assay may be to analyze the expression of preselected genes. Other functional methods of identifying phage antibodies known and available to those skilled in the art may be used.
In practicing the present invention, the resulting phage antibody library may contain antibodies reactive to antigens unique to the target cells and antibodies reactive to antigens present on both the target cells and non-target cells. It may be desirable to selectively remove the antibodies reactive to antigens not unique to the target cells. This may be accomplished by preadsorbing the phage antibody library with an excess of non-target cells to immunologically remove phage antibodies directed against antigens present on non-target cells. This additional step may be performed either prior to incubating the phage antibody library with the cell population, or prior to isolating monoclonal antibodies from the enriched library.
Alternatively, it is possible to preincubate the cell population with a saturating amount of antibodies having known specificity prior to incubating the cell population with the phage antibody library. This immunologically blocks the known antigen binding sites on the target cell surface, and avoids enriching phage antibodies having the known specificity.
The goal of selectively enriching phage antibodies directed against antigens present only on target cells and not on non-target cells can also be achieved by DNA subtraction hybridization. In this method, two cell type specific phage antibody libraries are generated using the present inventive method, one for the target cells and one for the non-target cells. DNA encoding antibodies directed against antigens present on both cell types are then removed from the first library by hybridizing DNA from the first library to an excess of DNA from the second library and subsequently removing the annealed hybrids. The resulting subtracted phage antibody library will then contain mostly antibodies directed against antigens unique to the target cells. Standard methods of DNA subtraction hybridization known to those skilled in the relevant art, or variations of these methods, may be used in this step.
The invention is further described in the following non-limiting examples.
EXEMPLIFICATION
Example 1
Laboratory mice are immunized against KGla cells by injection of the cells intraperitonially three times at intervals ranging from six weeks to six months. The KGla cell line is an available human myeloblastoid cell line, and is characterized in several publications, including Koeffler et al., Blood 56, 265-273 (1980).
Six days following the last injection, spleen cells are isolated from the animals, lymphocytes are separated on a Ficoll-Paque™ gradient, commercially available from Pharmacia LKB Biotechnology, Inc., Piscataway, New Jersey, and total RNA is prepared using standard, known techniques. A combinatorial phage antibody library of 10^ recombinants is prepared using standard protocols as described in Barbas et al., Methods 2, 119-124 (1991), and as described in further detail below.
KGla cells are incubated with phage particles from the combinatorial library in binding buffer on ice for 30 minutes, and then spun through a calf serum cushion three times. Phage particles bound to the surface of the cells are eluted in an acid buffer (such as 0.1 M HC1, adjusted with glycine to pH 2.2; and BSA lmg/ml), recovered, and used to infect XLl-Blue bacteria, available from Stratagene Cloning Systems, La Jolla, California. The phagemids in the infected bacteria are expanded in culture and rescued with helper phage VCSM13 to yield an enriched phage antibody library. The library is then used in another round of enrichment.
This enrichment process is repeated several times, four times in this example. Table 1 lists the number of phage particles recovered after each round of enrichment, showing a steady increase in the number of recovered phage particles after each round. In contrast, a negative control experiment (results not shown) using mouse thymocytes as the target cells for binding with the phage shows no increase in the number of phage particles recovered. Table 1
Enrichment of phage antibodies by direct affinity selection on the cell surface
Round 1 Round 2 Round 3 Round 4
No. phage 2 x lθ5 8 x K)5 20 x 105 20 x 105 recovered
Antigen binding fragments of the antibodies (Fab fragments) are produced from either the unenriched library or the final library after four rounds of enrichment and tested for reactivity to the KGla cells by indirect fluorescence- activated cell sorting (FACS) analysis. FIGURES 3(a) through 3(d) are histograms showing fluorescence patterns of KGla cells and mouse thymocytes stained with the unenriched (a,c) or enriched (b,d) antibody libraries. The abscissa indicates relative fluorescence intensity and the ordinate indicates relative cell number.
The staining of KGla with the unenriched library (a) is no different from that of the background, whereas staining with the enriched library (b) gives signals approximately twenty times more intense. In contrast, the staining of mouse thymocites with either the unenriched (c) or enriched (d) libraries are both indistinguishable from the background. The KGla cells and mouse thymocytes have different autofluorescence patterns, thus accounting for the difference in background staining. These results demonstrate that phage antibody libraries can be enriched by the inventive method of direct affinity selection on the cell surface to generate monoclonal antibodies highly reactive to target cells.
To determine the fraction of monoclonal antibodies in the enriched phage antibody library that are specific for KGla cells, Fab fragments are produced separately from ten individual clones picked at random from the library. FACS analysis of these samples (results not given) shows that the Fab fragments from all of the ten clones strongly react with KGla cells and with variable patterns, indicating that all of the ten monoclonal antibodies are specific for KGla and probably recognize at least several different surface antigens on the cells. By extension, the entire enriched antibody library most likely contains a large number of monoclonal antibodies recognizing many different surface antigens on KGla cells.
Example 2
KGla cells, which bear the human CD34 antigen on their surface, are stained with CD34-specific antibodies according to Civin et al., T.Immunol 133, 157-165 (1984), and spiked at a ratio of 1 to 10 or 1 to 100 into mouse thymocytes, which are CD34 antigen negative. The cell mixtures are incubated with an unenriched phage antibody library and sorted for CD34 antigen positive (CD34+) cells by FACS. Phage particles bound on the surface of the sorted cells are recovered by acid elution and used to infect XLl-Blue bacteria. An enriched phage antibody library is then produce by helper phage rescue of the phagemids in the infected bacteria and used in another round of enrichment. As shown in Table 2, the number of phage particles recovered from the sorted CD34+ cells increases dramatically after three rounds of selection, suggesting effective enrichment of specific phage antibody by the copurification method described in detail above.
Table 2
Enrichment of phage antibodies by copurification with target cells
(a) KGla and mouse thymocytes at a ratio of 1:10
Round 1 Round 2 Round 3
No. CD34+ cells sorted 250,000 250,000 283,000
No. phage recovered 1.5 x lO4 4.5 x lO4 50 x l04
(b) KGla and mouse thymocytes at a ratio of 1:100
Round 1 Round 2 Round 3
No. CD34+ cells sorted 52,000 63,000 80,000
No. phage recovered 0.6 x lO4 1.6 x lO4 10 x l04
Fab fragments are produced from the enriched library and used for staining KGla and mouse thymocytes. FACS analysis using these Fab fragments show a strong reaction with the KGla cells but no reaction with the mouse thymocytes (results not shown). Fab fragments from the unenriched library give signals similar to the background. This result demonstrates the feasibility of producing specific monoclonal antibodies directed against a rare population of cells using the combined strategies of cell surface selection and target cell copurification. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the invention claimed herein.
All cited literature are incorporated by reference in their entirety.

Claims

We claim:
1. Method for generating monoclonal antibodies directed against previously uncharacterized and unpurified antigens on the surface of target cells in a cell population, using a combinatorial library of antibodies expressed on the surface of filamentous phage particles, the method comprising the steps of:
A. incubating the library with the target cells under conditions sufficient to bind a portion of the phage particles to the target cells;
B. separating the target cells and the bound phage particles from unbound phage particles;
C. recovering the phage particles bound to the target cells;
D. amplifying the bound phage particles to create an enriched library; and
E. isolating from the enriched library monoclonal antibodies specific for the target cells.
2. The method of claim 1, wherein the target cells comprise a phenotypically defined target cell subpopulation and the cell population comprises a heterogeneous cell population, the method further comprising, prior to Step A: purifying the target cell subpopulation from the heterogeneous cell population.
3. The method of claim 1, wherein the target cells comprise a phenotypically defined target cell subpopulation and the cell population comprises a heterogeneous cell population, wherein Step B comprises: copurifying the target cell subpopulation and the bound phage particles from the heterogeneous cell population and unbound phage particles.
4. The method of claim 3, wherein Step B further comprises: copurifying the target cells and the bound phage particles by one method selected from the group consisting of: fluorescence-activated cell sorting (FACS); immunological panning; magnetic bead separation; and, affinity chromatography.
5. The method of claim 1, wherein the target cells comprise a defined cell type in a frozen tissue section, and Step B comprises: identifying the target cells by immunohistochemistry; and microdissecting the target cells and the bound phage particles from the tissue section.
6. The method of claim 1, wherein the phage particles are phage antibodies, and wherein Step B comprises: identifying functionally important phage antibodies bound to the target cells by assaying for the consequences of a phage antibody-target cell binding using one assay selected from the group consisting of: measuring intracellular calcium concentration; detecting cell activation, cell proliferation, or cell killing; detecting blocking of cell activation, cell proliferation, or cell killing; and, analyzing expression of preselected genes.
PCT/US1994/005124 1993-05-07 1994-05-04 Method for generating cell type specific phage antibody libraries WO1994026787A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5932393A 1993-05-07 1993-05-07
US08/059,323 1993-05-07

Publications (1)

Publication Number Publication Date
WO1994026787A1 true WO1994026787A1 (en) 1994-11-24

Family

ID=22022244

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/005124 WO1994026787A1 (en) 1993-05-07 1994-05-04 Method for generating cell type specific phage antibody libraries

Country Status (1)

Country Link
WO (1) WO1994026787A1 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997022972A2 (en) * 1995-12-15 1997-06-26 Pharmacia & Upjohn Company Method for the simultaneous detection of a therapeutic target for a disease state and its neutralizing antibody-like molecule
US5721342A (en) * 1989-11-13 1998-02-24 British Technology Group Limited Control of milk secretion
WO1998034110A1 (en) * 1997-01-31 1998-08-06 Active Biotech Ab In situ identification of target structures e.g. in vivo selection method for a phage library
WO1998039469A1 (en) * 1997-03-04 1998-09-11 Bio-Technology General Corp. Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs
WO1998049286A2 (en) * 1997-05-01 1998-11-05 Board Of Regents, The University Of Texas System Directed evolution of enzymes and antibodies
WO1999041402A2 (en) * 1998-02-11 1999-08-19 Maxygen, Inc. Targeting of genetic vaccine vectors
WO1999056129A1 (en) * 1998-04-24 1999-11-04 The Regents Of The University Of California Methods of selecting internalizing antibodies
WO2000014215A1 (en) * 1998-09-07 2000-03-16 Eberhard-Karls-Universität Tübingen Method for selecting peptides for the targeted transport of drugs and markers, and peptides discovered using said method
US6057098A (en) * 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
US6190856B1 (en) * 1996-05-22 2001-02-20 The Johns Hopkins University Methods of detection utilizing modified bacteriophage
WO2001025492A1 (en) * 1999-10-02 2001-04-12 Biosite Diagnostics Inc. Human antibodies
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US6277583B1 (en) * 1996-02-07 2001-08-21 Conjuchem, Inc. Affinity labeling libraries and applications thereof
US6680209B1 (en) 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
US6924359B1 (en) 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
US7045283B2 (en) 2000-10-18 2006-05-16 The Regents Of The University Of California Methods of high-throughput screening for internalizing antibodies
US7132510B2 (en) 2000-12-29 2006-11-07 Bio-Technology General (Israel) Ltd. Specific human antibodies for selective cancer therapy
US7135287B1 (en) 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
US7288249B2 (en) 1999-03-01 2007-10-30 Genentech, Inc. Antibodies for cancer therapy and diagnosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0460607A2 (en) * 1990-06-05 1991-12-11 Bristol-Myers Squibb Company Novel monoclonal antibody to novel antigen associated with human tumors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0460607A2 (en) * 1990-06-05 1991-12-11 Bristol-Myers Squibb Company Novel monoclonal antibody to novel antigen associated with human tumors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HARLOW et al., "Antibodies a Laboratory Manual", Published 1988, by COLD SPRING HARBOR LABORATORY (N.Y.), pages 496-497. *
J. IMMUNOLOGY, Vol. 135, No. 4, issued October 1985, LEDBETTER et al., "Antibodies to TP67 and TP44 Augment and Sustain Prolifferative Response of Activated T Cells", pages 2331-2336. *
NATURE, Vol. 308, issued 08 March 1984, HENDRICK et al., "Isolation of CDNA Clones Encoding T Cell-Specific Membrane-Associated Proteins", pages 149-153. *

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721342A (en) * 1989-11-13 1998-02-24 British Technology Group Limited Control of milk secretion
US6858384B2 (en) * 1995-06-07 2005-02-22 Crucell Holland B.V. Phage antibodies
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
WO1997022972A3 (en) * 1995-12-15 1997-08-21 Upjohn Co Method for the simultaneous detection of a therapeutic target for a disease state and its neutralizing antibody-like molecule
WO1997022972A2 (en) * 1995-12-15 1997-06-26 Pharmacia & Upjohn Company Method for the simultaneous detection of a therapeutic target for a disease state and its neutralizing antibody-like molecule
US6277583B1 (en) * 1996-02-07 2001-08-21 Conjuchem, Inc. Affinity labeling libraries and applications thereof
US6190856B1 (en) * 1996-05-22 2001-02-20 The Johns Hopkins University Methods of detection utilizing modified bacteriophage
WO1998034110A1 (en) * 1997-01-31 1998-08-06 Active Biotech Ab In situ identification of target structures e.g. in vivo selection method for a phage library
US6727062B1 (en) 1997-01-31 2004-04-27 Active Biotech Ab Identification of target structures E.G. in vivo selection method for a phage library
WO1998039469A1 (en) * 1997-03-04 1998-09-11 Bio-Technology General Corp. Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs
US6986986B1 (en) 1997-04-04 2006-01-17 Joe Buechler Polyvalent display libraries
US6057098A (en) * 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
WO1998049286A2 (en) * 1997-05-01 1998-11-05 Board Of Regents, The University Of Texas System Directed evolution of enzymes and antibodies
WO1998049286A3 (en) * 1997-05-01 1999-03-25 Univ Texas Directed evolution of enzymes and antibodies
WO1999041402A2 (en) * 1998-02-11 1999-08-19 Maxygen, Inc. Targeting of genetic vaccine vectors
WO1999041402A3 (en) * 1998-02-11 1999-11-11 Maxygen Inc Targeting of genetic vaccine vectors
WO1999056129A1 (en) * 1998-04-24 1999-11-04 The Regents Of The University Of California Methods of selecting internalizing antibodies
US8974792B2 (en) 1998-04-24 2015-03-10 The Regents Of The University Of California Internalizing erbB2 antibodies
US9388244B2 (en) 1998-04-24 2016-07-12 The Regents Of The University Of California Internalizing ErbB2 antibodies
US8173424B2 (en) 1998-04-24 2012-05-08 The Regents Of The University Of California Internalizing ErbB2 antibodies
US7892554B2 (en) 1998-04-24 2011-02-22 The Regents Of The University Of California Internalizing ErbB2 antibodies
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
WO2000014215A1 (en) * 1998-09-07 2000-03-16 Eberhard-Karls-Universität Tübingen Method for selecting peptides for the targeted transport of drugs and markers, and peptides discovered using said method
US7288249B2 (en) 1999-03-01 2007-10-30 Genentech, Inc. Antibodies for cancer therapy and diagnosis
US8388974B2 (en) 1999-07-01 2013-03-05 Yale University Neovascular-targeted immunoconjugates
US6924359B1 (en) 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
US7858092B2 (en) 1999-07-01 2010-12-28 Yale University Neovascular-targeted immunoconjugates
US8071104B2 (en) 1999-07-01 2011-12-06 Yale University Neovascular-targeted immunoconjugates
US7135287B1 (en) 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
WO2001025492A1 (en) * 1999-10-02 2001-04-12 Biosite Diagnostics Inc. Human antibodies
US7189515B2 (en) 1999-12-06 2007-03-13 Biosite, Inc. Human antibodies as detection reagents
US6680209B1 (en) 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
US7045283B2 (en) 2000-10-18 2006-05-16 The Regents Of The University Of California Methods of high-throughput screening for internalizing antibodies
US7132510B2 (en) 2000-12-29 2006-11-07 Bio-Technology General (Israel) Ltd. Specific human antibodies for selective cancer therapy

Similar Documents

Publication Publication Date Title
WO1994026787A1 (en) Method for generating cell type specific phage antibody libraries
Folgori et al. A general strategy to identify mimotopes of pathological antigens using only random peptide libraries and human sera.
US5646001A (en) Affinity-binding separation and release of one or more selected subset of biological entities from a mixed population thereof
Pappas et al. Cellular separations: a review of new challenges in analytical chemistry
Gerisch Univalent antibody fragments as tools for the analysis of cell interactions in Dictyostelium
JP3135126B2 (en) Method, assay, and therapeutic agent for obtaining diagnostic reagent based on clinical manifestation of disease
CN100494399C (en) Genotype typing method based on DNA chip and use thereof
EP0526577B1 (en) Methods for removing ligands from a particle surface
AU699568B2 (en) A method for identification of biologically active peptides and nucleic acids
JPH03277972A (en) Method of detecting listeria germ
JP3901222B2 (en) Compositions and methods for detection of antibody binding to cells
Sekine et al. Panning of multiple subsets of leukocytes on antibody-decorated poly (ethylene) glycol-coated glass slides
JP2002503085A (en) Classification of magnetically activated cells for protein production
EP0631633A1 (en) Reaction-based selection for expression of and concentration of catalytic moieties
CN113699156A (en) PD-1 aptamer, and screening method and application thereof
Cullis et al. Isolation of tissue culture-induced polymorphisms in bananas by representational difference analysis
Henn Separation of neuronal and glial cells and subcellular constituents
JP4729043B2 (en) Methods for screening antibody libraries
CN114544957A (en) Application of ADGRG1 as biomarker in preparation of kit for detecting hematopoietic stem cell in-vitro amplification efficiency
JP6959138B2 (en) Methods for Identifying Disease-Related CDR3 Patterns in the Immune Repertoire
AU756357B2 (en) Methods for identifying therapeutic targets
CN113429466B (en) Method for discovering aspergillus flavus strain to produce virulence indicator molecule
Yang et al. Single-Cell Proteomics Study of Immune Cell Diversity by Quantitating 465 Proteins
WO2023007793A1 (en) Cell sample preparation reagent
WO2021006353A1 (en) Method for amplifying nucleic acid using solid-phase carrier

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA